Bibliography
- LEBWOHL M, TYRING SK, HAMILTON TK et al.: A novel tageted T-cell modulator for plaque psoriasis. N. Engl. J. Med. (2003) 349:2004–2013.
- GORDON KB, PAPP KA, HAMILTON TK et al.: Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. "AMA (2003) 290:3073–3080.
- RAPP SR, FELDMAN SR, EXUM ML, FLEISCHER AB Jr, REBOUSSIN DM: Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol (1999) 41:401–407.
- GOTTLIEB A, KRUEGER JG, BRIGHT R et al: Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J. Am. Acad. Dermatol (2000) 42:428–435.
- PAPP P, BISSONNETTE R, KRUEGER JG et al.: The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. I Am. Acad. Dermatol (2001) 45:665–674.
- SPULS PI, WITKAMP L, BOSSUYT PM, BOS JD: A systematic review of five systemic treatments for severe psoriasis. Br: J. Dermatol (1997) 137:943–949.
- HEYDENDAEL VM, SPULS PI, OPMEER BC et al.: Methotrexate versus cyclosporine in moderate-to-severe chronic psoriasis. N Engl. I Med. (2003) 349:658–665.
- ELLIS CN, KRUEGER GG: Treatment ofchronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl. J. Med. (2001) 345:248–255.
- KRUEGER GG, CALLIS KP: Development and use of alefacept to treat psoriasis. J. Am. Acad. Der-mato]. (2003) 47\(Supp1.2):S87–S97.
- LEONARDI CL, POWERS JL, MATHESON RT et al.: Etanercept as monotherapy in patients with psoriasis.N Engl. J. Med. (2003) 349: 2014-2022.
- GOTTLIEB AB: Infliximab for psoriasis.J. Am. Acad. Der-mato]. (2003) 49\(Suppl. 2):S112-S117. Affiliation Sheila A Doggrell PhD DSc Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand E-mail: [email protected]